A Study on the Prevalence of Mutation of Cerebrotendinous Xanthomatosis (CTX)

Xanthomatosis, Cerebrotendinous Clinical Trial

— F-GENE  

Official title:

A Study on the Prevalence of Mutation of Cerebrotendinous Xanthomatosis (CTX) in Families With Kinship Bonds and at Least One Homozygous Patient

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT04218006
• Other study ID #: TR-CTX-003
• Status: Enrolling by invitation
• Start date: December 1, 2019
• Est. completion date: March 2022

Study information

• Verified date: March 2021
• Source: TRPHARM
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective, non-drug epidemological cohort study aimed to investigate the relatives of these cases with CTX-specific gene mutation and clinical features of CTX disease over CTX index cases diagnosed with CTX disease throughout the clinics in Turkey. Relatives included in the study (relatives of CTX index cases) will be taken into clinical and genetic evaluation. Relatives will not receive any experimental intervention or treatment because of their participation in the study. Therefore, this study does not include a treatment protocol or does not have a predetermined visit flow chart. However, relatives of CTX index cases should give consent to genetic testing.

Description:

WORK DESIGN STAGES:

1. The CTX index case will be identified and the CTX genetics will be reapproved. The following steps will be provided for all cases.

• Re-validation of CTX genetics: Cases of CTX indexes that are unrelated and clearly identified the CTX homozygous inheritance identified in the CYP27A1 gene by kinship.

• Documenting the nuclear and extended family structure and extracting family trees (interview with index cases and parents of index cases)

• Documentation of all potential symptoms compatible with CTX disease, including data based on the CTX suspicion index (Mignarri Index) in the nuclear and extended family

• Documentation of patients who have died due to unexpected death or unwillingness to participate in the study.

• Specific members of nuclear and extended family relatives will be contacted to propose genetic counseling. Approvals for genetic testing will be asked and necessary information forms will be provided. A total of 5 ml of blood will be collected from each patient for DNA analysis. Blood samples will be analyzed at the Damagen Genetic Diagnosis Center (Ankara), after which no samples will be stored and all samples will be destroyed.

• Collecting blood samples from index cases and, where possible, all nuclear family members (such as parents and siblings)

2. The target cohort will be defined in each family according to the interview results. If the study physician predicts that there are fewer than 50 patients in a large family for the study and follow-up period, this family will be excluded from the study. The initial objective will be to involve grandparents, all their children, married wives and grandchildren. This choice can be adapted by the physician depending on the special situation in the family according to the results of individuals who have undergone genetic mutation tests in the nuclear family, if any, and the definition of nuclear and extended relatives may change in consanguineous families. All extended family members of each identified CTX case will be invited to perform the following steps:

• Genetic counseling (ideally per family)

• Approvals for genetic testing will be asked and necessary information forms will be provided. A total of 5 ml of blood will be collected from each patient for DNA analysis. Blood samples will be analyzed at the Damagen Genetic Diagnosis Center (Ankara) and no samples will be stored after the analysis and all samples will be destroyed. Documentation of key data for each case

• Confirming that the family tree is correctly identified.

• Documenting patients who have died due to unexpected death or unwillingness to participate in the study.

• Perform limited neurological examination for key signs and symptoms and document it according to the CTX suspicion index (Mignarri Index).

3. Testing all samples by DNA sequencing for the identified mutation analysis. According to the results, large family cohort will be extracted. In some families, this number can reach up to 600-800 cases.

4. Re-inviting all study cases with disease genotypes for extended neurological examination and medical / genetic counseling.

5. To offer genetic counseling to all study patients with carrier genotypes so that they can make informed decisions about marriage and the next generation (the study coordinator will propose the medical follow-up of new cases diagnosed genetically as CTX).

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 800
• Est. completion date: March 2022
• Est. primary completion date: December 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• The family of each CTX index case should have more than 50 members in at least three generations.

• CTX index cases should be from different families.

• Index cases and relatives and / or legal representatives are required to be willing to give written informed consent.

Exclusion Criteria:

• Relatives of unconfirmed CTX index cases or non-homozygous CTX patients for disease-causing CTX mutation.

• The patient and / or his / her legal representative does not consent to participate in the study.

Related Conditions & MeSH terms

• Xanthomatosis, Cerebrotendinous

Intervention

Genetic:
• Mutation Analysis
Specific members of nuclear and extended family relatives will be contacted to propose genetic counseling. Approvals for genetic testing will be asked and necessary information forms will be provided. A total of 5 ml of blood will be collected from each patient for DNA analysis. Blood samples will be analyzed at the Damagen Genetic Diagnosis Center (Ankara), after which no samples will be stored and all samples will be destroyed.

Locations

Country	Name	City	State
Turkey	Osmaniye / Index Case 1 Family Village	Osmaniye

Sponsors (3)

Lead Sponsor	Collaborator
TRPHARM	Damagen Genetic Diagnostic Center, Klinar CRO

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of CTX mutation	Frequency of CTX mutation (affected or carrier mutation) among relatives	1 year
Secondary	Signs or symptoms compatible with CTX disease	Proportion of cases and relatives with current and / or past signs or symptoms compatible with CTX disease	1 year
Secondary	Mignarri Index	CTX disease scoring index values	1 Year
Secondary	Pedigree	A family tree of the index case	1 year